Synopsis: Healthcare stock fell up to 6.3% after mixed Q3FY26 results, with shares near ₹171 and market cap around ₹1,850 crore. EBITDA declined to ₹375 million, while net debt stood at ₹4,086 million. Occupancy dropped to 44%, and surgeries fell 8.5%, reflecting operational pressure.
The shares of the India multispeciality hospital plummeted up to 6.3 percent in today’s session from an intraday low after the company reported mixed Q3FY26 earnings.
With a market capitalization of Rs 1,850.21 crore, the shares of Shalby Ltd were trading at Rs 171.30 per share, decreasing around 5 percent as compared to the previous closing price of Rs 179.45 apiece.
Q3FY26 Highlights
The shares of Shalby Ltd have seen significant movement after announcing its financial performance in Q3FY26, in which revenue decreased by 1.3 percent on a year-on-year basis from Rs 275.63 crore in Q3FY25 to Rs 272.13 crore in Q3FY26. However, on a Quarter-on-Quarter basis, revenue decreased by 5 percent from Rs 285.43 crore in Q2FY26 to Rs 272.13 crore in Q3FY26.
Moreover, net loss turned into profit on a yearly basis from a loss of Rs 2.99 crore in Q3FY25 to a profit of Rs 1.28 crore in Q3FY26; meanwhile, on a quarter-on-quarter basis, net profit decreased by 82 percent from Rs 7.28 crore in Q2FY26 to Rs 1.28 crore in Q3FY26.
The company reported a marginal decline in overall performance during Q3 FY26, with EBITDA falling to Rs 375 million from Rs 393 million year-on-year. PBT also dropped to Rs 92 million compared to Rs 124 million. Net debt stood elevated at Rs 4,086 million as of December 2025, while annualized ROCE remained modest at 6.7%.
Shalby’s Q3 FY26 performance was largely driven by its core hospital, pharma, and franchise segment, contributing over 80% of total revenue at ₹224.96 crore with EBITDA of ₹32.23 crore. International operations added steady support, while the MedTech implant business remained marginally profitable. Overall, consolidated revenue stood average with EBITDA of ₹37.49 crore.
In Q3 FY26, the hospital business witnessed pressure across key operating metrics. Inpatient and outpatient volumes declined, leading to an 8.5% drop in total surgeries. Occupancy softened to 44%, though ARPOB improved marginally. While most specialties saw lower procedure counts, orthopaedics showed growth. Average length of stay increased, reflecting relatively higher case complexity during the quarter.
Shalby Limited is a leading multi-specialty healthcare provider in India, widely recognized for its expertise in joint replacement surgeries. Founded by Dr. Vikram Shah, the group operates a network of hospitals across India and overseas. It also has a presence in implants and medical technology, strengthening its integrated healthcare delivery model.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Shalby Shares Fall 6% After Announcing Q3 Results; Check Details appeared first on Trade Brains.